• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RCUS

    Arcus Biosciences Inc.

    Subscribe to $RCUS
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

    IPO Year: 2018

    Exchange: NYSE

    Website: arcusbio.com

    Peers

    $CRVS
    $ITOS
    $CANF

    Recent Analyst Ratings for Arcus Biosciences Inc.

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    11/9/2021$45.00 → $48.00Overweight
    Barclays
    10/15/2021$57.00Buy
    BTIG Research
    See more ratings

    Arcus Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arcus Biosciences upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

      2/26/25 7:16:55 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Arcus Biosciences with a new price target

      H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

      10/21/24 7:58:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Arcus Biosciences with a new price target

      Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

      10/8/24 7:34:04 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Arcus Biosciences with a new price target

      BofA Securities initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $33.00

      11/18/22 7:57:17 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Arcus Biosciences with a new price target

      Morgan Stanley initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $40.00

      10/11/22 7:50:24 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Arcus Biosciences with a new price target

      Citigroup reiterated coverage of Arcus Biosciences with a rating of Buy and set a new price target of $53.00 from $42.00 previously

      11/19/21 9:16:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barclays reiterated coverage on Arcus Biosciences with a new price target

      Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $60.00 from $48.00 previously

      11/19/21 7:43:41 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Arcus Biosciences with a new price target

      SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $100.00 from $68.00 previously

      11/18/21 7:54:26 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barclays reiterated coverage on Arcus Biosciences with a new price target

      Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $48.00 from $45.00 previously

      11/9/21 7:27:28 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Arcus Biosciences with a new price target

      BTIG Research resumed coverage of Arcus Biosciences with a rating of Buy and set a new price target of $57.00

      10/15/21 7:47:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care